Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRMD CorMedix	$12.93 +2.5%	$12.41	$4.67 ▼ $17.43	$965.21M	1.71	3.24 million shs	2.46 million shs
GYRE Gyre Therapeutics	$8.14 -1.0%	$7.65	$6.11 ▼ $19.00	$783.99M	1.8	79,304 shs	61,069 shs
SIGA Siga Technologies	$8.50 -0.9%	$6.96	$4.95 ▼ $11.91	$608.65M	0.94	591,319 shs	466,389 shs
VYGR Voyager Therapeutics	$3.73 +0.3%	$3.25	$2.64 ▼ $8.27	$206.90M	0.9	860,468 shs	581,545 shs

10 Best Stocks to Own: Fall 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRMD CorMedix	0.00%	+25.17%	+16.80%	+5.29%	+162.80%
GYRE Gyre Therapeutics	0.00%	+13.21%	+10.15%	-28.28%	-18.44%
SIGA Siga Technologies	0.00%	-5.13%	+26.87%	+41.90%	-28.99%
VYGR Voyager Therapeutics	0.00%	+18.79%	+15.84%	+13.03%	-42.35%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CRMD CorMedix	3.2054 of 5 stars	4.4	1.0	0.0	2.5	0.0	1.9
GYRE Gyre Therapeutics	0.0775 of 5 stars	0.0	1.0	0.0	1.7	0.8	0.0
SIGA Siga Technologies	2.1573 of 5 stars	0.0	2.0	0.0	2.7	0.8	3.1
VYGR Voyager Therapeutics	3.7019 of 5 stars	3.6	1.0	4.6	1.6	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRMD CorMedix	2.88	Moderate Buy	$16.71	29.27% Upside
GYRE Gyre Therapeutics	3.00	Buy	N/A	N/A
SIGA Siga Technologies	0.00	N/A	N/A	N/A
VYGR Voyager Therapeutics	3.13	Buy	$13.25	255.15% Upside

Current Analyst Ratings Breakdown

Latest VYGR, CRMD, SIGA, and GYRE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/8/2025	CRMD CorMedix	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$20.00 ➝ $17.00
8/7/2025	VYGR Voyager Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$9.00 ➝ $8.00
6/30/2025	CRMD CorMedix	D Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
6/30/2025	CRMD CorMedix	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold
6/30/2025	CRMD CorMedix	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$20.00
6/24/2025	CRMD CorMedix	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$15.00 ➝ $20.00
6/23/2025	CRMD CorMedix	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00
6/20/2025	CRMD CorMedix	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Outperform ➝ Moderate Buy	$13.00 ➝ $17.00

(Data available from 8/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRMD CorMedix	$121.48M	7.95	N/A	N/A	$2.96 per share	4.37
GYRE Gyre Therapeutics	$105.76M	7.41	$0.20 per share	41.22	$1.34 per share	6.07
SIGA Siga Technologies	$179.64M	3.39	$0.84 per share	10.16	$2.92 per share	2.91
VYGR Voyager Therapeutics	$80M	2.59	N/A	N/A	$4.40 per share	0.85

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRMD CorMedix	-$17.93M	$0.75	17.24	13.76	N/A	42.11%	42.73%	34.19%	10/29/2025 (Estimated)
GYRE Gyre Therapeutics	$12.09M	$0.01	814.81	∞	N/A	4.08%	7.67%	6.19%	N/A
SIGA Siga Technologies	$59.21M	$1.13	7.52	6.80	N/A	45.73%	40.52%	35.62%	N/A
VYGR Voyager Therapeutics	-$65M	-$1.85	N/A	N/A	N/A	-253.49%	-37.65%	-28.89%	N/A

Latest VYGR, CRMD, SIGA, and GYRE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	Q2 2025	GYRE Gyre Therapeutics	$0.03	$0.02	-$0.01	$0.04	$30.80 million	$26.77 million
8/7/2025	Q2 2025	CRMD CorMedix	$0.20	$0.28	+$0.08	$0.28	$29.88 million	$39.74 million
8/6/2025	Q2 2025	VYGR Voyager Therapeutics	-$0.48	-$0.57	-$0.09	-$0.57	$9.50 million	$5.20 million
8/5/2025	Q2 2025	SIGA Siga Technologies	N/A	$0.49	N/A	$0.49	N/A	$81.12 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRMD CorMedix	N/A	N/A	N/A	N/A	N/A
GYRE Gyre Therapeutics	N/A	N/A	N/A	N/A	N/A
SIGA Siga Technologies	N/A	N/A	N/A	N/A	N/A
VYGR Voyager Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRMD CorMedix	N/A	7.82	7.52
GYRE Gyre Therapeutics	N/A	5.40	3.19
SIGA Siga Technologies	N/A	10.09	8.52
VYGR Voyager Therapeutics	N/A	5.43	5.43

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRMD CorMedix	34.18%
GYRE Gyre Therapeutics	23.99%
SIGA Siga Technologies	55.40%
VYGR Voyager Therapeutics	48.03%

Insider Ownership

Company	Insider Ownership
CRMD CorMedix	5.30%
GYRE Gyre Therapeutics	10.00%
SIGA Siga Technologies	1.95%
VYGR Voyager Therapeutics	6.39%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRMD CorMedix	30	74.65 million	70.69 million	Optionable
GYRE Gyre Therapeutics	40	96.31 million	86.68 million	No Data
SIGA Siga Technologies	40	71.61 million	70.21 million	Optionable
VYGR Voyager Therapeutics	100	55.47 million	51.93 million	Optionable

VYGR, CRMD, SIGA, and GYRE Headlines

Recent News About These Companies

Voyager Therapeutics Extends Cash Runway to 2028

August 13, 2025 | msn.com

Research Analysts Offer Predictions for VYGR Q3 Earnings

August 12, 2025 | americanbankingnews.com

Truist Financial Keeps Their Buy Rating on Voyager Therapeutics (VYGR)

August 11, 2025 | theglobeandmail.com

Voyager Therapeutics (VYGR) Receives a Buy from Oppenheimer

August 11, 2025 | theglobeandmail.com

Equities Analysts Offer Predictions for VYGR Q3 Earnings

August 11, 2025 | marketbeat.com

Voyager Therapeutics (NASDAQ:VYGR) Releases Earnings Results, Misses Estimates By $0.09 EPS

August 10, 2025 | marketbeat.com

Voyager Therapeutics (NASDAQ:VYGR) Given New $8.00 Price Target at Wedbush

August 10, 2025 | americanbankingnews.com

Voyager Therapeutics (VYGR) Receives a Buy from Canaccord Genuity

August 9, 2025 | theglobeandmail.com

Voyager Therapeutics (NASDAQ:VYGR) Price Target Lowered to $8.00 at Wedbush

August 8, 2025 | marketbeat.com

Voyager Therapeutics (VYGR) Reports Q2 Loss, Lags Revenue Estimates

August 6, 2025 | zacks.com

Voyager Reports Second Quarter 2025 Financial and Operating Results

August 6, 2025 | globenewswire.com

Voyager Therapeutics, Inc. (NASDAQ:VYGR) Given Average Recommendation of "Buy" by Analysts

July 30, 2025 | marketbeat.com

Voyager Therapeutics (VYGR) to Release Quarterly Earnings on Tuesday

July 29, 2025 | marketbeat.com

Voyager 1 and 2: From Earth to Interstellar Space: The Final Frontier Awaits

July 21, 2025 | msn.com

Read the NASA ‘Voyager Declaration’ Letter of Dissent

July 21, 2025 | nytimes.com

Mascarene Partners Acquires Voyager Trucking

July 18, 2025 | finance.yahoo.com

Mascarene buys US waste services company Voyager Trucking

July 18, 2025 | realassets.ipe.comR

Voyager Therapeutics adds new gene therapy to Alzheimer’s program

July 18, 2025 | bioworld.comB

Mascarene to acquire waste services transport firm Voyager Trucking Corporation

July 18, 2025 | pehub.com

Looking Beyond Voyager 1 And 2

July 17, 2025 | msn.com

Robert Beltran on Star Trek: I “Risked being fired” Because I Didn’t Like What Was Happening in the Last 3 Years of Voyager

July 16, 2025 | fandomwire.comF

New MarketBeat Followers Over Time

Media Sentiment Over Time

VYGR, CRMD, SIGA, and GYRE Company Descriptions

CorMedix NASDAQ:CRMD

$12.93 +0.32 (+2.54%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$12.94 +0.01 (+0.04%)

As of 08/15/2025 07:54 PM Eastern

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.

Gyre Therapeutics NASDAQ:GYRE

$8.14 -0.08 (-0.97%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$8.11 -0.03 (-0.37%)

As of 08/15/2025 06:45 PM Eastern

Gyre Therapeutics, Inc., a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases. In addition, it advances a product pipeline in China, including Pirfenidone, for dermatomyositis interstitial lung disease, systemic sclerosis-associated interstitial lung disease, and pneumoconiosis, as well as for diabetic kidney disease; and product candidates for acute-on-chronic liver failure, chronic obstructive pulmonary disease, and pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California.

Siga Technologies NASDAQ:SIGA

$8.50 -0.08 (-0.93%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$8.50 0.00 (0.00%)

As of 08/15/2025 07:54 PM Eastern

SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.

Voyager Therapeutics NASDAQ:VYGR

$3.73 +0.01 (+0.27%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$3.74 +0.02 (+0.40%)

As of 08/15/2025 07:35 PM Eastern

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time